

Form PTO-1449 (modified)

Atty. Docket No.

INRP:087/GNS

Serial No.

09/413,109

List of Patents and Publications for Applicant's

Applicant

Wei-Wei Zhang and Jack A. R. th

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

October 6, 1999

Group:

1636

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 2

Other Art

See Page 2



TECH CENTER 1600/2900

JUN 27 2001

RECEIVED

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
<i>PC</i>	A5	5,252,479	10/12/93	Srivastava	435	235.1	
<i>PC</i>	A6	5,362,623	11/08/94	Vogelstein <i>et al.</i>	435	6	
<i>PC</i>	A7	5,496,731	3/5/96	Xu, <i>et al.</i>	435	320.1	
<i>PC</i>	A8	5,527,676	6/18/96	Vogelstein <i>et al.</i>	435	6	
<i>PC</i>	A9	5,532,220	7/2/96	Lee <i>et al.</i>	514	44	
<i>PC</i>	A10	5,585,362	12/17/96	Wilson <i>et al.</i>	514	44	
<i>PC</i>	A11	5,747,469	5/5/98	Roth <i>et al.</i>	514	44	
<i>PC</i>	A12	6,090,566	07/18/00	Vogelstein <i>et al.</i>	435	7.23	
<i>PC</i>	A13	5,328,470	07/12/94	Nabel <i>et al.</i>			
<i>PC</i>	A14	5,166,320	11/24/92	Wu <i>et al.</i>			

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
<i>PC</i>	B11	0174608	9/5/85	Europe <i>EPO</i>			
<i>PC</i>	B12	0351585	6/23/89	Europe <i>EPO</i>			
<i>PC</i>	B13	0390323	10/3/90	Europe <i>EPO</i>			
<i>PC</i>	B14	0475623	8/23/91	Europe <i>EPO</i>			
<i>PC</i>	B15	WO 94/08026	4/14/94	PCT			
<i>PC</i>	B16	WO 95/14101	5/26/95	PCT			
<i>PC</i>	B17	WO 95/14102	5/26/95	PCT			

25043152.1

EXAMINER:

David Hugo

DATE CONSIDERED:

8/27/01

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.

INRP:087/GNS

Serial No.

09/413,109

List of Patents and Publications for Applicant's

Applicant

Wei-Wei Zhang and Jack A. Roth

RECEIVED

JUN 27 2001

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

October 6, 1999

Group:

1636

TECH CENTER 1600/2900

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 2

Other Art

See Page 2

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
22	B18	WO 95/23867	9/8/95	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
22	C66	Bacchetti, <i>et al.</i> , "Inhibition of Cell Proliferation by and Adenovirus Vector Expressing the Human Wild Type p53 Protein," <i>International Journal of Oncology</i> , 3:781-788, 1993
	C67	Baker <i>et al.</i> , "Chromosome 17 Deletions and p53 Gene Mutations in Colorectal Carinomas," <i>Science</i> , 244:217-221, April 1989.
	C68	Baker <i>et al.</i> , "p53 Gene Mutations Occur in Combination with 17p Allelic Deletions as Late Events in Colorectal Tumorigenesis," <i>Cancer Research</i> , 50:7717-7722, December 1990.
	C69	Baker <i>et al.</i> , "Suppression of Human Colorectal Carcinoma Cell Growth by Wild-Type p53," <i>Science</i> , 249:912-915, August 1990.
	C70	Bargonetti <i>et al.</i> , "Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication," <i>Cell</i> , 65:1083-1091, 1991.
	C71	Berkner, "Development of adenovirus vectors for the expression of heterologous genes", <i>BioTechniques</i> , 6(7):616-629, 1988.
	C72	Blenis, "Signal transduction via the MAP kinases: Proceed at your own RSK", <i>Proc. Natl. Acad. Sci. USA</i> , 90:5889-5892, 1993.
	C73	Brachman <i>et al.</i> , "p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines", <i>Cancer Res.</i> , 53:3667-3669, 1993.
	C74	Brown <i>et al.</i> , "Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines," <i>Int. J. Cancer</i> , 55:678-684, 1993.
	C75	Brown <i>et al.</i> , "Mutant p53 confers cisplatin-sensitivity to resistant ovarian tumour cells with elevated wild-type p53," <i>Proc. Am. Assoc. Cancer Res.</i> , 34:355, Abstract #2116, 1993.
02	C76	Capecchi, "Altering the genome by homologous recombination", <i>Science</i> , 244:1288-1292, 1989.

25043152.1

EXAMINER:

David Sugo

DATE CONSIDERED:

8/27/01

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

INRP:087/GNS

Serial No.

09/413,109

RECEIVED

List of Patents and Publications for Applicant's

Applicant

Wei-Wei Zhang and Jack A. Roth

JUN 27 2001

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

October 6, 1999

Group:

1636

TECH CENTER 1600/2900

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 2

Other Art

See Page 2

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>il</i>	C77	Carter <i>et al.</i> , "Adenovirus Containing a Deletion of the Early Region 2A Gene Allows Growth of Adeno-Associated Virus with Decreased Efficiency," <i>Virology</i> , 191:473-476, 1992.
	C78	Chang <i>et al.</i> , "Inhibition of intratracheal lung cancer development by systemic delivery of E1A," <i>Oncogene</i> , 13:1405-1412, 1996.
	C79	Chang <i>et al.</i> , "Restoration of the G1 Checkpoint and the Apoptotic Pathway Mediated by Wild-type p53 Sensitizes Squamous Cell Carcinoma of the Head and Neck to Radiotherapy," <i>Arch Otolaryngol Head Neck Surg.</i> , 123:507-512, 1997.
	C80	Cheng <i>et al.</i> , "Suppression of acute lymphoblastic leukemia by the human wild-type p53 gene," <i>Cancer Res.</i> , 52:222-226, 1992.
	C81	Clarke, <i>et al.</i> , "Thymocyte Apoptosis Induced by p53-Dependent and Independent Pathways," <i>Nature</i> , 362:849-852, April 29, 1993.
	C82	Coleman <i>et al.</i> , "Radiation and chemotherapy sensitizers and protectors", <i>Critical Reviews In Oncology/Hematology</i> , 10(Issue 3):225-252, 1990.
	C83	Colicos <i>et al.</i> , "Construction of a recombinant adenovirus containing the <i>denV</i> gene from bacteriophage T4 which can partially restore the DNA repair deficiency in xeroderma pigmentosum fibroblasts," <i>Carcinogenesis</i> , 12(2):249-255, 1991.
	C84	Comings, "A general theory of carcinogenesis," <i>Proc. Natl. Acad. Sci. USA</i> , 70(12-Part I):3324-3328, 1973.
	C85	Cai <i>et al.</i> , "Stable expression of the wild-type p53 gene in human lung cancer cells after retrovirus-mediated gene transfer," <i>Hum. Gene Ther.</i> , 4:617-24, 1993.
	C86	Copies of slides from presentation by Jack A. Roth on September 19, 1996.
	C87	Culver <i>et al.</i> , "Gene Therapy for Cancer," <i>TIG</i> , 10(5):174-178, 1994.
	C88	Culver, <i>et al.</i> , "In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors," <i>Science</i> , 256:1550-1552, 1992.
<i>il</i>	C89	Curiel <i>et al.</i> , "High-efficiency gene transfer mediated by adenovirus coupled to DNA-polylysine complexes," <i>Human Gene Therapy</i> , 3:147-154, 1992.

25043152.1

EXAMINER:

David Gyo

DATE CONSIDERED:

8/27/01

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.
INRP:087/GNSSerial No.
09/413,109

List of Patents and Publications for Applicant's

Applicant
Wei-Wei Zhang and Jack A. Roth

RECEIVED

JUN 27 2001

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
October 6, 1999Gr up:
1636

TECH CENTER 1600/2900

U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 2Other Art
See Page 2

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
ge	C90	Davidson <i>et al.</i> , "A model system for in vivo gene transfer into the central nervous system using adenoviral vector," <i>Nature Genetics</i> , 3:219-223, 1993.
	C91	Diller <i>et al.</i> , "p53 Functions as a Cell Cycle Control Protein in Osteosarcomas," <i>Molecular and Cellular Biology</i> , 10(11):5772-5781, November 1990.
	C92	Donehower, "Tumor suppressor gene p53 and apoptosis," <i>Cancer Bull.</i> , 46(2):161-166, 1994.
	C93	Dorigo <i>et al.</i> , "Sensitization of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild-type p53 function," <i>J. Neurosurg.</i> , 88:535-540, 1998.
	C94	El Rouby <i>et al.</i> , "p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression," <i>Blood</i> , 82(11):3452-3459, 1993.
	C95	El-Deiry <i>et al.</i> , "WAF1, a potential mediator of p53 tumor suppression," <i>Cell</i> , 75:817-825, 1993.
	C96	Eliyahu <i>et al.</i> , "p53 - A potential suppressor gene?" <i>J. Cell. Biochem.</i> , UCLA Symposia on Molecular and Cellular Biology, Abstracts, 19 th Annual Meeting, Supplement 14C:264, #I 030, 1990.
	C97	Eliyahu <i>et al.</i> , "Meth A Fibrosarcoma Cells Express Two Transforming Mutant p53 Species," <i>Oncogene</i> , 3:313-321, 1988.
	C98	Eliyahu <i>et al.</i> , "Wild-type p53 Can Inhibit Oncogene-Mediated Focus Formation," <i>Proc. Nat. Acad. Sci. USA</i> , 85:8763-8767, November 1989.
	C99	Fan <i>et al.</i> , "The role of p53 in cell cycle arrest and apoptosis induced by multiple chemotherapeutic agents in Burkitt's lymphoma cells," <i>Proc. Am. Assoc. Cancer Res.</i> , 35:311, Abstract #1851, 1994.
	C100	Finlay <i>et al.</i> , "The p53 Proto-Oncogene Can Act as a Suppressor of Transformation," <i>Cell</i> , 57:1083-1093, June 1989.
g	C101	<i>Hematology/Oncology Clinics of North America</i> , v. 4, n. 3, <i>Bone Marrow Transplantation</i> , edited by Stephen J. Foreman, M.D., 1990.

25043152.1

EXAMINER:

David Guzo

DATE CONSIDERED:

8/27/01

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

INRP:087/GNS

09/413,109

List of Patents and Publications for Applicant's

Applicant

Wei-Wei Zhang and Jack A. Roth

RECEIVED

JUN 27 2001

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

October 6, 1999

Group:

1636

TECH CENTER 1600/2900

Patent Documents

See Page 1

Foreign Patent Documents

See Page 2

Other Art

See Page 2

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
82	CI02	Fornace, Jr., "Induction by radiation of mammalian genes associated with growth-arrest and apoptosis, and the role for the p53 tumor suppressor in their regulation," <i>Proc. Am. Assoc. Cancer Res.</i> , 35:681-682, 1994.
	CI03	Friedmann, "Gene therapy of cancer through restoration of tumor-suppressor functions?" <i>Cancer</i> , 70(6-Suppl):1810-1817, 1992.
	CI04	Fritsche <i>et al.</i> , "Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents," <i>Oncogene</i> , 8:307-318, 1993.
	CI05	Fritsche <i>et al.</i> , "Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents," published erratum, <i>Oncogene</i> , 8(9):2605, 1993.
	CI06	Fujiwara <i>et al.</i> , "Induction of chemosensitivity in human lung cancer cells <i>in vivo</i> by adenovirus-mediated transfer of the wild-type p53 gene," <i>Cancer Res.</i> , 54:2287-2291, 1994.
	CI07	Fujiwara <i>et al.</i> , "A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis," <i>Cancer Res.</i> , 53:4129-4133, 1993.
	CI08	Fujiwara <i>et al.</i> , "Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model," <i>J. Natl. Cancer Inst.</i> , 86(19):1458-1462, 1994.
	CI09	Gebhardt <i>et al.</i> , "A Tumor Suppressor Proto-Oncogene p53 Can Block Progression Through the Cell Cycle," Association of American Physicians, American Society for Clinical Investigation, American Federation for Clinical Research, Subspecialty Meetings, Sheraton Washington Hotel, Washington, DC, May 6, 1990, pg. 447A, Abstract.
	CI10	Georges, <i>et al.</i> , "Prevention of Orthotopic Human Lung Cancer Growth by Intratracheal Instillation of a Retroviral Antisense K-ras Construct," <i>Cancer Research</i> , 53:1743-1746, 1993.
	CI11	Graham and Prevec, "Manipulation of Adenovirus Vectors," In: <i>Methods in Molecular Biology: Gene Transfer and Expression Protocols</i> , E.J. Murray (ed.), The Humana Press, Inc., Vol. 7, Chapter 11, pp. 109-128, 1991.
	CI12	Gregory, <i>et al.</i> , "Tumor Suppressor of Gene Therapy of Cancer: Adenoviral Mediated Gene Transfer of p53 into Human Tumor Cell Lines," <i>J. Cell. Biochem. Supp.</i> 18a, p. 237.
8	CI13	Gridley <i>et al.</i> , "Evaluation of radiation effects against C6 glioma in combination with vaccinia virus-p53 gene therapy," <i>International J. Oncology</i> , 13:1093-1098, 1998.

25043152.1

EXAMINER:

David Myers

DATE CONSIDERED:

8/27/01

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

INRP:087/GNS

Serial No.

09/413,109

List of Patents and Publications for Applicant's

Applicant

Wei-Wei Zhang and Jack A. Roth

RECEIVED

JUN 27 2001

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

October 6, 1999

Gr up:

1636

TECH CENTER 1600/2900

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 2

Other Art

See Page 2

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
gz	CI14	Gudkov <i>et al.</i> , "Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interaction cytotoxic drugs, from human topoisomerase II cDNA", <i>Proc. Natl. Acad. Sci. USA</i> , 90:3231-3235, 1993.
	CI15	Gutierrez <i>et al.</i> , "Gene Therapy for Cancer," <i>The Lancet</i> , 339:715-721, 1992.
	CI16	Hanania <i>et al.</i> , "Genetic chemoprotection of hematopoietic cells and genetic chemosensitization of breast cancer cells in a mouse cancer gene therapy model," <i>Proc. Amer. Assoc. Cancer Res.</i> , Vol. 37, #2362, March 1996.
	CI17	Harper <i>et al.</i> , "Enhancement of antitumor effects of p53 gene therapy by combination with DNA-damaging agents," <i>Cancer Gene Therapy</i> , Vol. 3, 6, Conf. Suppl., S41-42, 1996.
	CI18	Hecht <i>et al.</i> , "Comparison of wildtype and mutated p53 protein expression induced by UV irradiation of cultured cells," <i>FASEB Journal</i> , 8:A667, #3870, 1994.
	CI19	Hinds <i>et al.</i> , "Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes," <i>Cell Growth and Differentiation</i> , 1(12):571-580, 1990.
	CI20	Hinds <i>et al.</i> , "Mutation is Required to Activate the p53 Gene for Cooperation with the <i>ras</i> Oncogene and Transformation," <i>Journal of Virology</i> , 63(2):739-746, February 1989.
	CI21	Hinds <i>et al.</i> , "The p53 Proto-Oncogene Can Suppress Transformation by Other Oncogenes, and Mutations in the Proto-Oncogene Can Activate the Gene for Transformation," <i>In: Common Mechanisms of Transformation by Small DNA Tumor Viruses</i> , Luis P. Villarreal (ed.), Chapter 7, pp. 83-101, 1989.
	CI22	Hitt <i>et al.</i> , "Adenovirus E1A under the Control of Heterologous Promoters: Wide Variation in E1A Expression Levels Has Little Effect on Virus Replication," <i>Virology</i> , 179:667-678, 1990.
	CI23	Hodgson, "Advances in Vector Systems for Gene Therapy," <i>Exp. Opin. Ther. Patents</i> , 5(5):459-468, 1995
	CI24	Houghten, "Peptide libraries: criteria and trends," <i>Technical Focus</i> , 9(7):235-239, 1993.
gz	CI25	Huang <i>et al.</i> , "Suppression of the Neoplastic Phenotype by Replacement of the RB Gene in Human Cancer Cells," <i>Science</i> , 242:1563-1566, December 1988.

25043152.1

EXAMINER:

David S. Suggs

DATE CONSIDERED:

8/27/01

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

INRP:087/GNS

Serial No.

09/413,109

RECEIVED

List of Patents and Publications for Applicant's

Applicant

Wei-Wei Zhang and Jack A. Roth

JUN 27 2001

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

October 6, 1999

Group:

1636

TECH CENTER 1600/290

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 2

Other Art

See Page 2

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>gz</i>	C126	Huston <i>et al.</i> , "Medical applications of single-chain antibodies," <i>Internatl. Rev. Immun.</i> , 10(2-3):195-217, 1993.
	C127	Itoh <i>et al.</i> , "The polypeptide encoded by the cDNA for human cell surface antigen <i>Fas</i> can mediate apoptosis," <i>Cell</i> , 66:233-243, 1991.
	C128	Jayawickreme <i>et al.</i> , "Creation and functional screening of a multi-use peptide library," <i>Proc. Natl. Acad. Sci. USA</i> , 91:1614-1618, 1994.
	C129	Jolly, "Viral vector systems for gene therapy," <i>Cancer Gene Therapy</i> , 1(1):51-64, 1994.
	C130	Kamb <i>et al.</i> , "A cell cycle regulator potentially involved in genesis of many tumor types," <i>Science</i> , 264:436-440, 1994.
	C131	Kaneko <i>et al.</i> , "Induction of apoptosis and p53 protein by adriamycin and hyperthermia in a rat mammary adenocarcinoma cell line," <i>Proc. Am. Assoc. Cancer Res.</i> , 35:314, #1871, 1994.
	C132	Kastan <i>et al.</i> , "Participation of p53 in the Cellular Response to DNA Damage," <i>Cancer Research</i> , 51:6304-6311, 1991.
	C133	Kastan <i>et al.</i> , "p53 and other molecular controls of the response to DNA damage," <i>J. Cell. Biochem.</i> , 9(18C):164, 1994.
	C134	Kastan, "Discussion of Dr. Kastan's presentation," <i>Adv. Exp. Med. Biol.</i> , 339:295-296, 1993.
	C135	Kemp <i>et al.</i> , "p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis," <i>Nature Genetics</i> , 8(1):66-69, 1994.
	C136	Kern <i>et al.</i> , "Identification of p53 as a sequence-specific DNA-binding protein," <i>Science</i> , 252:1708-1711, 1991.
	C137	Klessig <i>et al.</i> , "Introduction, Stable Integration, and Controlled Expression of a Chimeric Adenovirus Gene Whose Product is Toxic to the Recipient Human Cell," <i>Molecular and Cellular Biology</i> , 4(7): 1354-1362, July 1984.
	C138	Knudson, Jr., "Mutation and cancer: Statistical study of retinoblastoma," <i>Proc. Natl. Acad. Sci. USA</i> , 68(4):820-823, 1971.
<i>gz</i>	C139	Kuerbitz <i>et al.</i> , "Wild-type p53 is a cell cycle checkpoint determinant following irradiation," <i>Proc. Natl. Acad. Sci. USA</i> , 89:7491-7495, 1992.

25043152.1

EXAMINER:

David Guzz

DATE CONSIDERED:

8/27/01

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

INRP:087/GNS

09/413,109

List of Patents and Publications for Applicant's

Applicant

Wei-Wei Zhang and Jack A. Roth

RECEIVED

JUN 27 2001



INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

October 6, 1999

Group:

1636

TECH CENTER 1600/2900

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 2

Other Art

See Page 2

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
gr	C140	Lamb and Crawford, "Characterization of the Human p53 Gene," <i>Molecular and Cellular Biology</i> , 6(5):1379-1385, May 1986.
	C141	Lane, "A death in the life of p53," <i>Nature</i> , 362:786-787, 1993.
	C142	Lee and Bernstein, "p53 mutations increase resistance to ionizing radiation," <i>Proc. Natl. Acad. Sci. USA</i> , 90(12):5742-5746, 1993.
	C143	Lee <i>et al.</i> , "Molecular basis of tumor suppression by the human retinoblastoma gene," UCLA Symposia on Molecular and Cellular Biology, Abstracts, 19 th Annual Meeting, Supplement 14C, #I 001, 1990.
	C144	Lesoon-Wood <i>et al.</i> , "Systemic gene therapy with a liposome-p53 complex reduces the growth and metastases of a malignant human breast cancer in nude mice," <i>Proc. Annu. Meet. Am. Assoc. Cancer Res.</i> , Vol. 36, pp. A2509, 1995.
	C145	Levine <i>et al.</i> , "The p53 growth suppressor gene," UCLA Symposia on Molecular and Cellular Biology, Abstracts, 19 th Annual Meeting, Supplement 14C:264, #I 030, 1990.
	C146	Levine <i>et al.</i> , "The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis," <i>Br. J. Cancer</i> , 69(3):409-416, 1994.
	C147	Levine <i>et al.</i> , "The p53 Growth Suppressing Gene Can Inhibit Transformation by Other Oncogenes," <i>The Journal of Cell Biology</i> , The American Society for Cell Biology, Twenty-ninth Annual Meeting, Houston, Texas, November 5-9, 1989, Abstract 502.
	C148	Li <i>et al.</i> , "A cancer family syndrome in twenty-four kindreds," <i>Cancer Res.</i> , 48:5358-5362, 1988.
	C149	Loganzo, Jr. <i>et al.</i> , "Stabilization of p53 protein is a critical response to UV radiation in human melanocytes: Implications for melanoma development," <i>Mol. Cell. Differ.</i> , 2(1):23-43, 1994.
	C150	Lotem and Sachs, "Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents," <i>Blood</i> , 82(4):1092-1096, 1993.
gr	C151	Lotem and Sachs, "Regulation by <i>bcl-2</i> , <i>c-myc</i> , and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukemic cells," <i>Cell Growth Differ.</i> , 4(1):41-47, 1993.

25043152.1

EXAMINER:

David G. [Signature]

DATE CONSIDERED:

8/27/01

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

Serial N .

INRP:087/GNS

09/413,109

List of Patents and Publications for Applicant's

Applicant

Wei-Wei Zhang and Jack A. Roth

RECEIVED

JUN 27 2001

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

October 6, 1999

Group:

1636

TECH CENTER 1600/2900

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 2

Other Art

See Page 2

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
Je	C152	Lowe <i>et al.</i> , "p53 is Required for Radiation Induced Apoptosis in Mouse Thymocytes," <i>Nature</i> 362:847-849, April 29, 1993.
	C153	Lowe <i>et al.</i> , "p53-dependent apoptosis modulates the cytotoxicity of anticancer agents," <i>Cell</i> , 74:957-967, 1993.
	C154	Maity <i>et al.</i> , "The molecular basis for cell cycle delays following ionizing radiation: a review," <i>Radiother. Oncol.</i> , 31(1):1-13, 1994.
	C155	Malkin <i>et al.</i> , "Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms," <i>Science</i> , 250:1233-1238, 1990.
	C156	Malkin <i>et al.</i> , "Mutant p53 Confers Tumorigenicity to a Cell Line Lacking p53: Evidence for a Second p53 Function in Tumor Formation," <i>Blood</i> , 76(10, Suppl. 1):238a, Abstract 944, 1990.
	C157	Mansour <i>et al.</i> , "Introduction of a <i>lacZ</i> reporter gene into the mouse <i>int-2</i> locus by homologous recombination," <i>Proc. Natl. Acad. Sci. USA</i> , 87:7688-7692, 1990.
	C158	Marshall, "Hot lips and phosphorylation of protein kinases," <i>Nature</i> , 367:686, 1994.
	C159	Marshall, "Gene Therapy's Growing Pains," <i>Science</i> , 269:1050-1055, 1995
	C160	McIlwrath <i>et al.</i> , "Cell cycle arrests and radiosensitivity of human tumor cell lines: Dependence on wild-type p53 for radiosensitivity," <i>Cancer Res.</i> , 54(14):3718-3722, 1994.
	C161	Mercer <i>et al.</i> , "Antiproliferative effects of wild type human p53," UCLA Symposia on Molecular and Cellular Biology, Abstracts, 19 th Annual Meeting, Supplement 14C:264, #I 029, 1990.
	C162	Mercer <i>et al.</i> , "Negative Growth Regulation in a Glioblastoma Tumor Cell Line that Conditionally Expresses Human Wild-Type p53," <i>Proc. Natl. Acad. Sci. USA</i> , 87:6166-6170, August 1990.
	C163	Merritt <i>et al.</i> , "The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice," <i>Cancer Res.</i> , 54:614-617, 1994.
	C164	Michalovitz <i>et al.</i> "Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53," <i>Cell</i> , 62:671-680, 1990.
CT	C165	Miller and Vile, "Targeted Vectors for Gene Therapy," <i>FASEB Journal</i> , 9:190-199, 1995.

25043152.1

EXAMINER:

David Yu

DATE CONSIDERED:

8/27/01

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket N .

Serial N .

INRP:087/GNS

09/413,109

RECEIVED

List of Patents and Publications for Applicant's

Applicant

Wei-Wei Zhang and Jack A. Roth

JUN 27 2001

INFORMATION DISCLOSURE STATEMENT

Filing Date:

October 6, 1999

Group:

1636

TECH CENTER 1600/2900

(Use several sheets if necessary)

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 2

Other Art

See Page 2

**Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
gc	C166	Minna <i>et al.</i> , "The molecular pathogenesis of lung cancer involves the accumulation of a large number of mutations in dominant oncogenes and multiple tumor suppressor genes (recessive oncogenes)," UCLA Symposia on Molecular and Cellular Biology, Abstracts, 19 th Annual Meeting, Supplement 14C:264, #1 003, 1990.
	C167	Miyake <i>et al.</i> , "Enhancement of Chemosensitivity in Human Bladder Cancer Cells by Adenoviral-Mediated p53 Gene Transfer," <i>Anticancer Res.</i> , 18:3087-92, 1998.
	C168	Nabeya <i>et al.</i> , "The mutational status of p53 protein in gastric cancer cell lines predicts sensitivity to chemotherapeutic agents," <i>Proc. Am. Assoc. Cancer Res.</i> , 35:602, Abstract #3591, 1994.
	C169	Neve, "Adenovirus Vectors Enter the Brain," <i>Trends Neuroscience</i> , 16(7):251-253, 1993.
	C170	Nguyen <i>et al.</i> , "Delivery of the p53 tumor suppressor gene into lung cancer cells by an adenovirus/DNA complex," <i>Cancer Gene Therapy</i> , 4(3):191-198, 1997.
	C171	Nielsen <i>et al.</i> , "Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts," <i>Pro. Annu. Meet. Am. Assoc. Cancer Res.</i> , Vol. 37, pp. A2317, 1996.
	C172	Nigro <i>et al.</i> , "Mutations in the p53 Gene Occur in Diverse Human Tumour Types," <i>Nature</i> , 342:705-708, December 1989.
	C173	O'Connor <i>et al.</i> , "Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines," <i>Cancer Res.</i> , 53:4776-4780, 1993.
	C174	O'Connor <i>et al.</i> , "Relationship between p53, cyclin E-cdk2 kinase complexes and G1 arrest induced by ionizing radiation in human cells," <i>Proc. Am. Assoc. Cancer Res.</i> , 35:635, Abstract #3785, 1994.
	C175	Ogawa <i>et al.</i> , "Novel Combination Therapy For Human Colon Cancer With Adenovirus-Mediated Wild-Type p53 Gene Transfer and DNA-Damaging Chemotherapeutic Agent," <i>Int. J. Cancer</i> , 73:367-370, 1997.
✓	C176	Orkin, <i>et al.</i> , "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy," December 7, 1995
gc	C177	Paull <i>et al.</i> , "The synthesis of XTT: a new tetrazolium reagent that is bioreducible to a water-soluble formazan," <i>J. Heterocyclic Chem.</i> , 25:911-914, 1988.

25043152.1

EXAMINER:

David M. G...

DATE CONSIDERED:

8/27/01

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

INRP:087/GNS

09/413,109

List of Patents and Publications for Applicant's

Applicant

Wei-Wei Zhang and Jack A. Roth

INFORMATION DISCLOSURE STATEMENT

RECEIVED

JUN 27 2001

(Use several sheets if necessary)

Filing Date:

October 6, 1999

Group:

1636 TECH CENTER 1600/2900

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 2

Other Art

See Page 2

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C178	Petty <i>et al.</i> , "Expression of the p53 tumour suppressor gene product is a determinant of chemosensitivity," <i>Biochem. and Biophys. Res. Comm.</i> , 199(1):264-270, 1994.
	C179	Pfarr <i>et al.</i> , "Differential Effects of Polyadenylation Regions on Gene Expression in Mammalian Cells," <i>DNA</i> , 5(2):115-122, 1986.
	C180	Phillips <i>et al.</i> , "Transition-state characterization: a new approach combining inhibitor analogues and variation in enzyme structure," <i>Biochem.</i> , 31:959-963, 1992.
	C181	Pirollo <i>et al.</i> , "p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy," <i>Oncogene</i> , 14:1735-46, 1997.
	C182	<i>Proceedings of the American Association for Cancer Research</i> , 36:21, March 1995.
	C183	Rajan <i>et al.</i> , "Simian Virus 40 Small-t Does Not Transactivate RNA Polymerase II Promoters in Virus Infections," <i>J. Virology</i> , 65(12):6553-6561, 1991.
	C184	Rau <i>et al.</i> , "Response of p53 to treatment with actinomycin D in human mammary carcinoma cell lines," <i>J. Cancer Res. Clin. Oncol.</i> , 120:R108, 1994.
	C185	Revet <i>et al.</i> , "Homologous DNA targeting with RecA protein-coated short DNA probes and electron microscope mapping on linear duplex molecules," <i>J. Mol. Biol.</i> , 232:779-791, 1993.
	C186	Romer and Friedman, "Mechanisms of action of the p53 tumor suppressor and prospects for cancer gene therapy by reconstitution of p53 function," <i>In: Annals of the New York Academy of Science, Gene Therapy for Neoplastic Diseases</i> , 716:265-282 (1994).
	C187	Roth, "Gene Replacement Strategies for Therapy and Prevention of Lung Cancer," <i>Proceedings Annual Meeting of American Assoc. Cancer Res.</i> , 35:692-3, 1994.
	C188	Roth, <i>et al.</i> , "Retrovirus-Mediated Wild-Type p53 Gene Transfer to Tumors of Patients with Lung Cancer," <i>Nature Medicine</i> , 2:985-991, 1996
	C189	Sager, "Tumor Suppressor Genes: The Puzzle and the Promise," <i>Science</i> , 246:1406-1412, December 1989.
or	C190	Saris <i>et al.</i> , "Treatment of murine primary brain tumors with systemic interleukin-2 and tumor-infiltrating lymphocytes," <i>J. Neurosurg.</i> , 76:513-519, 1992.

25043152.1

EXAMINER:

David G...

DATE CONSIDERED:

8/21/01

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

Serial N .

INRP:087/GNS

09/413,109

List of Patents and Publications for Applicant's

Applicant

Wei-Wei Zhang and Jack A. Roth

INFORMATION DISCLOSURE STATEMENT

RECEIVED

JUN 27 2001

(Use several sheets if necessary)

Filing Date:

October 6, 1999

Group:

1636

TECH CENTER 1600/2900

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 2

Other Art

See Page 2



Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
g2	C191	Schuler <i>et al.</i> , "A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer," <i>Human Gene Therapy</i> , 9:2075-2082, 1998.
	C192	Shaulsky <i>et al.</i> , "Involvement of wild-type p53 in pre-B-cell differentiation <i>in vitro</i> ," <i>Proc. Natl. Acad. Sci. USA</i> , 88:8982-8986, 1991.
	C193	Shaw <i>et al.</i> , "Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line," <i>Proc. Natl. Acad. Sci. USA</i> , 89(10):4495-4499, 1992.
	C194	Shay <i>et al.</i> , "A role for both RB and p53 in the regulation of human cellular senescence," <i>Experimental Cell Res.</i> , 196:33-39, 1991.
	C195	Shenk, "Group C Adenoviruses as Vectors for Gene Therapy," in <i>Viral Vectors</i> , 1995, Academic Press.
	C196	Slichenmyer <i>et al.</i> , "Loss of p53-associated G1 Checkpoint Does Not Decrease Cell Survival following DNA Damage," <i>Cancer Research</i> , 53:4164-4168, 1993.
	C197	Spitz <i>et al.</i> , "Adenoviral mediated p53 gene therapy enhances radiation sensitivity of colorectal cancer cell lines," <i>Proc. Amer. Assoc. Cancer Res.</i> , Vol. 37, #2366, March 1996.
	C198	Srivastava <i>et al.</i> , "Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome," <i>Nature</i> , 348:747-749, 1990.
	C199	Steel, "Cyclins and cancer: wheels within wheels," <i>Lancet</i> , 343:931-932, 1994.
	C200	Stein <i>et al.</i> , "Antisense oligonucleotides as therapeutic agents - is the bullet really magical?" <i>Science</i> , 261:1004-1012, 1993.
	C201	Su <i>et al.</i> , "Transformation and radiosensitivity of human diploid skin fibroblasts transfected with SV40 T-antigen mutants defective in RB and p53 binding domains," <i>Int. J. Radiat. Biol.</i> , 62(4):461-468, 1992.
	C202	Takayama <i>et al.</i> , "Growth suppression of lung cancer by recombinant adenovirus-mediated human p53 and p21 cDNA transfer," <i>Proceedings Annual Meeting, American Society of Clinical Oncology</i> , 16: A1597, 1997.
g2	C203	Tang <i>et al.</i> , "Potential Application of Gene Therapy to Lung Cancer," <i>Seminars in Oncology</i> , 20(4):368-373, 1993.

25043152.1

EXAMINER:

David G. [Signature]

DATE CONSIDERED:

8/27/01

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.

Serial N .

INRP:087/GNS

09/413,109

List of Patents and Publications for Applicant's

Applicant

Wei-Wei Zhang and Jack A. Roth

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

October 6, 1999

Group:

1636

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 2


Other Art

See Page 2

RECEIVED

JUN 27 2001

TECH CENTER 1600/2900



Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
je	C204	Thomas <i>et al.</i> , "High-fidelity gene targeting in embryonic stem cells by using sequence replacement vectors," <i>Molec. Cell. Biol.</i> , 12(7):2919-2923, 1992.
	C205	Tishler, <i>et al.</i> , "Increases in Sequence Specific DNA Binding by p53 Following Treatment with Chemotherapeutic and DNA Damaging Agents, <i>Cancer Research</i> , 53:2212-2216, 1993.
	C206	Tseng and Brown, "Antisense oligonucleotide technology in the development of cancer therapeutics," <i>Cancer Gene Therapy</i> , 1(1):65-71, 1994.
	C207	Ullrich <i>et al.</i> , "Human wild-type p53 adopts a unique conformational and phosphorylation state <i>in vivo</i> during growth arrest of glioblastoma cells," <i>Oncogene</i> , 7:1635-1643, 1992.
	C208	Unger <i>et al.</i> , "Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition, and transformation suppression," <i>Molec. Cell. Biol.</i> , 13(9):5186-5194, 1993.
	C209	Van de Waterbeemd, "Recent progress in QSAR-technology," <i>Drug Design and Discovery</i> , 9:277-285, 1993.
	C210	Varghese <i>et al.</i> , "The role of p53 and ras genes in radiation-induced transformation of immortalized human epidermal keratinocytes," <i>Proc. Am. Assoc. Cancer Res.</i> , 35:91, Abstract #542, 1994.
	C211	Vogelstein and Kinzler, "p53 function and dysfunction," <i>Cell</i> , 70:523-526, 1992.
	C212	Vogelstein <i>et al.</i> , "Genetic Alterations During Colorectal-Tumor Development," <i>The New England Journal of Medicine</i> , 319(9):525-532, 1988.
	C213	Wagner <i>et al.</i> , "Coupling of adenovirus to transferrin-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes," <i>Proc. Natl. Acad. Sci. USA</i> , 89:6099-6103, 1992.
	C214	Wang and Finer, "Second-generation adenovirus vectors," <i>Nature Medicine</i> , 2:714-716, June 6, 1996
je	C215	Weislow <i>et al.</i> , "New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity," <i>J. Nat. Cancer Inst.</i> , 81(8):577-586, 1989.

25043152.1

EXAMINER:

David King

DATE CONSIDERED:

8/22/01

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

INRP:087/GNS

09/413,109

List of Patents and Publications for Applicant's

Applicant

Wei-Wei Zhang and Jack A. Roth

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

October 6, 1999

Group:

1636

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 2

Other Art

See Page 2

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>gc</i>	C216	Wilkinson <i>et al.</i> , "Constitutive and enhanced expression from the CMV major IE promoter in a defective adenovirus vector," <i>Nucleic Acids Research</i> , 20(9):2233-2239, 1992.
<i> </i>	C217	Wills, et al, "Tumor Suppressor Gene Therapy of Cancer: Adenoviral Mediated Gene Transfer of p53 and Retinoblastoma cDNA into Human Tumor Cell Lines," <i>J. Cell. Biochem. Supp.</i> 18c, p. 204.
<i> </i>	C218	Wu <i>et al.</i> , "Receptor-mediated gene delivery <i>in vivo</i> ," <i>J. Biol. Chem.</i> , 266(22):14338-14342, 1991.
<i> </i>	C219	Xu <i>et al.</i> , "Parental Gene Therapy with p53 Inhibits Human Breast Tumors <i>In Vivo</i> Through a Bystander Mechanism Without Evidence of Toxicity," <i>Human Gene Therapy</i> , 8:177-185, 1997.
<i> </i>	C220	Yamada and Ohyama, "Radiation and apoptosis," <i>Gan To Kagaku Ryoho</i> , 21(5):602-607, 1994.
<i> </i>	C221	Yonish-Rouach <i>et al.</i> , "Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6," <i>Nature</i> , 352:345-347, 1991.
<i>↙</i>	C222	Yoshimura <i>et al.</i> , "Expression of the human cystic fibrosis transmembrane conductance regulator gene in the mouse lung after <i>in vivo</i> intratracheal plasmid-mediated gene transfer," <i>Nucl. Acid Res.</i> , 20(12):3233-3240, 1992.
<i>gc</i>	C223	Zhu <i>et al.</i> , "Systemic gene expression after intravenous DNA delivery into adult mice," <i>Science</i> , 261:209-211, 1993.

25043152.1

EXAMINER:

David S. ...

DATE CONSIDERED:

8/27/01

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)